SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Denies Approval of XenoPort, Inc., GlaxoSmithKline RLS Drug; Xenoport

February 18, 2010 | 
1 min read
Bookmark and Share

Reuters -- U.S. regulators have denied approval for a drug from XenoPort (XNPT.O) and GlaxoSmithKline (GSK.L) to treat restless legs syndrome because of a potential link to cancer found in rats.
FDA Approvals Regulatory
GSK
MORE ON THIS TOPIC
Creative pattern made with a syringe on pastel pink background. Vaccine for Coronavirus infection. Pandemic concept.
COVID-19
FDA assembles vaccine experts to update COVID-19 formulation
May 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
May 27, 2026
 · 
4 min read
 · 
Tristan Manalac
Isometric Office chair with vacancy sign isolated on blue background. Employment, vacancy and hiring job vector concept
Regulatory
Makary’s reforms will live on at FDA even as leadership turns over
May 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
May 27, 2026
 · 
2 min read
 · 
Jef Akst